Tomotherapy Treatment for Mesothelioma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00469196 |
Recruitment Status
:
Completed
First Posted
: May 4, 2007
Last Update Posted
: April 6, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mesothelioma | Procedure: Tomotherapy | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 18 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Tomotherapy Treatment for Mesothelioma |
Study Start Date : | October 2006 |
Actual Primary Completion Date : | May 2015 |
Actual Study Completion Date : | May 2015 |

-
Procedure: Tomotherapy
- Quality of Life [ Time Frame: 6 months ]Disease-specific symptom control rate post-treatment, based on Palliation Index [7].
- Breathing Function [ Time Frame: 6 months ]Pulmonary function test results at 1, 3 and 6 months post treatment
- Survival/Response Rate [ Time Frame: 6 months ]performance status at 1, 3 and 6 months post treatment; and overall survival

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- histologic mesothelioma
- refused/ineligible for surgery or chemotherapy
- life expectancy >3 months
Exclusion Criteria:
- contraindications to thoracic radiotherapy
- unable to lie flat for duration of radiation therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00469196
Canada, Alberta | |
Cross Cancer Institute | |
Edmonton, Alberta, Canada, T5N 2R8 |
Principal Investigator: | Rufus Scrimger, MD | AHS Cancer Control Alberta |
Responsible Party: | AHS Cancer Control Alberta |
ClinicalTrials.gov Identifier: | NCT00469196 History of Changes |
Other Study ID Numbers: |
LU-11-0077 / 22933 |
First Posted: | May 4, 2007 Key Record Dates |
Last Update Posted: | April 6, 2016 |
Last Verified: | March 2016 |
Keywords provided by AHS Cancer Control Alberta:
mesothelioma tomotherapy |
Additional relevant MeSH terms:
Mesothelioma Adenoma Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Neoplasms, Mesothelial |